Results 11 to 20 of about 185,056 (259)

ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells

Scientific Reports, 2017
Management of infection with hepatitis B virus (HBV) remains a global health problem. Persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is responsible for modest curative efficacy of currently licensed drugs. Novel gene
Tristan Scott, Buhle Moyo, Samantha Nicholson, Mohube Betty Maepa, Koichi Watashi, Abdullah Ely, Marc S. Weinberg, Patrick Arbuthnot   +7 more
doaj   +1 more source

Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case–control study from Uganda and South Africa

Antiviral Therapy, 2022
Background Relationships between distinct antiretroviral therapy (ART) adherence patterns and risk of drug resistance are not well understood. Methods We conducted a nested case–control analysis within a longitudinal cohort study of individuals ...
Anisha Tyagi, Yao Tong, Dustin J Rabideau, Zahra Reynolds, Tulio De Oliveira, Richard Lessells, Gideon Amanyire, Catherine Orrell, Stephen Asiimwe, Benjamin Chimukangara, Jennifer Giandhari, Sureshnee Pillay, Jessica E Haberer, Mark J Siedner,   +14 more
doaj   +1 more source

A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir

Antiviral Therapy, 2022
Ergotism is a rare cause of peripheral vasoconstriction with varying presentation depending on the affected vessels. Coronary vasospasm is a rare, potentially fatal manifestation of ergotism.
Cheng-En Wu, Chun-Hsien Wu, Shih-Hung Tsai, Wen-I Liao   +3 more
doaj   +1 more source

HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective

Antiviral Therapy, 2023
Contemporary antiretroviral therapy (ART) regimens have high barriers to the development of drug resistance. However, resistance to earlier antiretrovirals and uncommon cases of resistance to contemporary ART illustrate the continued need for good ...
Andrew Carr, Nicola E Mackie, Roger Paredes, Kiat Ruxrungtham   +3 more
doaj   +1 more source

Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ

Antiviral Therapy, 2023
Background Polyamines are involved in several cellular processes and inhibiting their synthesis affects chikungunya virus (CHIKV) replication and translation, and, therefore, reduces the quantity of infectious viral particles produced.
Lucero Rojas-Luna, Araceli Posadas-Modragón, Amanda M Avila-Trejo, Verónica Alcántara-Farfán, Lorena I Rodríguez-Páez, José Angel Santiago-Cruz, Marvin O Pastor-Alonso, J Leopoldo Aguilar-Faisal   +7 more
doaj   +1 more source

Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives

Antiviral Therapy, 2023
In endemic areas, hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfection is common, and patients with coinfection have a higher risk of developing liver disease such as hepatocellular carcinoma, liver fibrosis and cirrhosis.
Quratulain Maqsood, Aleena Sumrin, Maryam Iqbal, Saima Younas, Nazim Hussain, Muhammada Mahnoor, Abdul Wajid   +6 more
doaj   +1 more source

A convenient method to generate and maintain poly(A)-encoding DNA sequences required for in vitro transcription of mRNA

BioTechniques, 2019
Generating mRNA in vitro to encode therapeutic or cell-modifying proteins is rapidly gaining favor. An important factor that determines efficiency of translation from in vitro transcribed mRNA is the length of the 3′ poly(A) sequence.
Patrick Arbuthnot, Abdullah Ely, Kristie Bloom   +2 more
doaj   +1 more source

Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation

Antiviral Therapy, 2023
Background Cytomegalovirus (CMV) infection is a frequent complication in haematopoietic cell/solid organ transplant (HCT/SOT) recipients. Previous studies report all-cause mortality rates of 31% and 50% in HCT/SOT recipients post-treatment initiation ...
Marielle Bassel, Dorothy Romanus, Tien Bo, Aimee K Sundberg, Sandra Okala, Ishan Hirji   +5 more
doaj   +1 more source

Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations

Molecular Therapy: Nucleic Acids, 2016
Primary microRNA (pri-miRNA) mimics are important mediators of effective gene silencing and are well suited for sustained therapeutic applications. Pri-miRNA mimics are processed in the endogenous miRNA biogenesis pathway, where elements of the secondary
Fiona T van den Berg, John J Rossi, Patrick Arbuthnot, Marc S Weinberg   +3 more
doaj   +1 more source

Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study

Antiviral Therapy, 2022
Background Tenofovir alafenamide (TAF) is a new anti-hepatitis B virus nucleotide analogue that can cause dyslipidaemia in AIDS patients, but the effect of TAF on blood lipids in patients with chronic hepatitis B (CHB) is unknown.
Yeqiong Zhang, Zhipeng Li, Qiumin Luo, Wenxiong Xu, Lu Wang, Shu Zhu, Liang Peng, Chan Xie   +7 more
doaj   +1 more source